CRISPR Therapeutics AG — Director's Dealing 2016

Oct 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: GLAXOSMITHKLINE PLC (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-18	Stock Option	$14.00	A	30000	Acquired	2026-10-18	Common Shares (30000)	Indirect

Footnotes

F1: This stock option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. The stock option was granted to Simeon J. George as director's compensation. As a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon J. George is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.